By directly blocking PTHrP action in bone, these novel targeted antagonists may prevent the outgrowth of breast cancer bone metastases, thereby inhibiting bone metastatic tumor cells from seeding metastases in other tissues and ultimately reducing the risk of organ failure and patient death. Here, PTHLH is linked to breast cancer.